Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of cetrorelix pamoate intermittent IM administration on ECG, PK and PD parameters in healthy male volunteers - a Thorough QT assesment to address the ICH-E14 guidelines

Next Previous
Search
Trial Profile

Assessment of cetrorelix pamoate intermittent IM administration on ECG, PK and PD parameters in healthy male volunteers - a Thorough QT assesment to address the ICH-E14 guidelines

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetrorelix (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Benign prostatic hyperplasia
  • Focus Adverse reactions
  • Sponsors AEterna Zentaris Inc; Celerion

    • Most Recent Events

    • 05 Mar 2011 Pharmacokinetic and pharmacodynamic results presented at the 112th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 08 Oct 2009 New trial record.
    • 30 Sep 2009 Primary endpoint 'no increase in heart rate-corrected QT interval' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top